Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils

@article{RasmussenTorvik2007GeneticSF,
  title={Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils},
  author={Laura J. Rasmussen-Torvik and Donna D. McAlpine},
  journal={Depression and Anxiety},
  year={2007},
  volume={24}
}
This article examines evidence for the potential benefit of genetic testing for SSRI response, as well as potential ethical and practical implications of the implementation of this test into standard psychiatric practice. We reviewed three areas of the literature: the burden of treatment‐resistant and treatment‐intolerant major depressive disorders, the evidence for the value of genetic testing to predict drug response, and the ethical and practical issues of genetic testing in usual care… Expand
Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment
TLDR
An effect of CNR1 gene in the etiology of MD and clinical response to citalopram is suggested, suggesting a better response to antidepressant treatment throughout the follow-up. Expand
Gene Regulation by Drugs Used to Treat Mood Disorders
TLDR
This project aimed to establish the effects of Antidepressant and mood stabiliser drugs on gene regulation, and in doing so, advance the field by detecting specific transcripts and biochemical pathways involved in drug response. Expand
Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism
TLDR
The authors aim to give an overview of the published studies analyzing the influence of CYP highly polymorphic loci on antidepressant treatment in order to translate the acquired knowledge to a clinical level. Expand
A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder.
TLDR
A meta-review is conducted to identify predictors of response to antidepressant therapy in order to select robust input features for machine learning models of treatment response, and highlights the importance of large-scale research initiatives and clinically accessible biomarkers. Expand
Methodological and Statistical Issues in the Use of Biomarkers in Clinical and Research Studies
TLDR
There are many methodologi cal and statistical issues that must be kept in mind as biomarkers are validated in research studies and before they can be considered useful for clinical practice. Expand
Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults
TLDR
Patients with two or more prior treatment failures are considered to have treatment-resistant depression (TRD); these TRD patients represent a complex population with a disease that is difficult to manage. Expand
Biomarkers in Psychiatry : Potentials, Pitfalls, and Pragmatics
Advances in fundamental neurobiology, neuroimaging, neurophysiology, behavioral genetics, and other current high-throughput "omics" fields have yielded considerable advances in understanding theExpand
Psychomotor retardation in depression: Biological underpinnings, measurement, and treatment
TLDR
A synthesis of the literature on psychomotor retardation in depression is provided with the goal of enhanced awareness for clinicians and researchers to further elucidate the biological underpinnings of depression and optimize its treatment. Expand
Prospective evaluation of specialist inpatient treatment for refractory affective disorders.
TLDR
Most patients with depression highly resistant to prior treatment respond to specialist and intensive multimodal inpatient therapy, and this was an observational study without any untreated control group. Expand
Serotonin and emotional processing: Does it help explain antidepressant drug action?
  • C. Harmer
  • Medicine, Psychology
  • Neuropharmacology
  • 2008
TLDR
Functional neuroimaging studies suggest that these early antidepressant effects involve fronto-limbic and extra-striate circuitry suggestive of actions on both the initial appraisal and attentional processing of affective stimuli, which may provide a framework for linking psychological and biological processes in emotional disorders and their treatment. Expand
...
1
2
...

References

SHOWING 1-10 OF 49 REFERENCES
Pharmacogenetics of antidepressant medication intolerance.
TLDR
Pharmacodynamic differences among patients due to variant 5-HT(2A) receptors appear to be more important than pharmacokinetic variation in determining paroxetine intolerance and pharmacogenetic markers may be useful in predicting antidepressant treatment outcome. Expand
The pharmacogenomics of selective serotonin reuptake inhibitors
TLDR
It is the hope that the identification of genetic components influencing the interindividual variability in response to treatment with SSRI will eventually facilitate the development of a customised SSRI treatment. Expand
Naturalistic study of the early psychiatric use of citalopram in the United States
TLDR
Citalopram administered at an average dose of 23.6mg/day was associated with favorable outcomes and was generally well tolerated, and Nausea (9.8%) and headache (7.3%) were the most often reported adverse events. Expand
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
TLDR
Combinations of polymorphisms in pharmacokinetic and pharmacodynamic pathways of relevance might contribute to identify genotypes associated with best and worst responders and they may also identify susceptibility to adverse drug reactions. Expand
Pharmacogenetics of psychotropic drug response.
TLDR
Initial research into the pharmacogenetics of psychotrop drug response suggests that specific genes may influence phenotypes associated with psychotropic drug administration. Expand
Response, partial response, and nonresponse in primary care treatment of depression.
TLDR
A substantial number of adequately treated patients did not respond to antidepressant therapy, and some of these patients may be considered undertreated or treatment-resistant according to current treatment guidelines recommending dose increases or medication switches for less than adequate clinical response. Expand
Diagnosis and definition of treatment-resistant depression
  • M. Fava
  • Medicine, Psychology
  • Biological Psychiatry
  • 2003
TLDR
An accurate and systematic assessment of treatment-resistant depression is a challenge to both clinicians and researchers, with the use of clinician-rated or self-rated instruments being perhaps quite helpful. Expand
Categorizing genetic tests to identify their ethical, legal, and social implications.
TLDR
This approach to test categorization allows a rapid determination of the predominant ELSI concerns for different kinds of genetic tests and identifies the data most urgently needed for test evaluation. Expand
Sequence Analysis of the Serotonin Transporter and Associations with Antidepressant Response
TLDR
An association between response to SSRIs and deoxyribonucleic acid variation at the serotonin transporter locus is supported and a potentially important functional variant that contributes to this association and a possible biologic mechanism that could mediate its effect is identified. Expand
Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review
TLDR
Current information is insufficiently reliable as a basis for implementing genetic testing in the diagnostic work-up of the depressive patient, according to a systematic review of the literature on the influence of polymorphisms in the serotonin transporter gene. Expand
...
1
2
3
4
5
...